Pharmaceutical

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

1 year ago

23andMe Announces CEO’s Take-Private Proposal

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and…

1 year ago

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…

1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support…

1 year ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ETNEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE)…

1 year ago

Kura Oncology to Report Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…

1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development,…

1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone…

1 year ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical…

1 year ago